EN DE
STOCK COMPARISON

Cyclopharm vs McKesson: Fair Value & Quality

Both stocks run through our valuation models. Here is how Cyclopharm (CYC) and McKesson (MCK) compare, as of Sep 25, 2026.

As of Sep 25, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Cyclopharm trades at A$0.46 versus a fair value of A$0.08 (-83%), while McKesson trades at $881 versus $819 (-7%).
Cyclopharm
CYC.AU · AUD · Health Care
-83%
upside to fair value
overvalued
PriceA$0.46
Fair ValueA$0.08
Quality34/100
McKesson
MCK · USD · Health Care
-7%
upside to fair value
fairly valued
Price$881
Fair Value$819
Quality66/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green is the better side of a row, red the weaker one (for valuation multiples: lower = cheaper). Grey rows are for reference only and are not scored.

betterweakerfor reference, not scored

CyclopharmMcKesson
Valuation
n/aP/E (TTM)22.7×
1.64×P/S (TTM)0.27×
1.95×P/BNegative equity
n/aEV/EBITDA16.1×
n/aPEG1.57×
−82.6%Fair value upside−6.9%
n/aDividend yield0.4%
n/aDividend per share$3.17
Profitability
-52%Operating margin2%
n/aEBIT margin trend (5Y)1.60×
-49%Return on equityNegative equity
-20%Return on assets5%
Growth
11%Revenue growth (YoY)6%
11.7%Avg. growth/yr (3Y)13.4%
17.1%Avg. growth/yr (5Y)11.1%
n/aValue creation/yr+40.2%
Balance & size
n/aInterest coverage (EBIT/interest)26.1×
n/aDebt / equityNegative equity
$53MMarket cap$109B
expensiveGrowth qualityhealthy

McKesson leads: 1 to 6 metric wins.

n/a = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Cyclopharmof which business quality 34 · market factors 19 McKessonof which business quality 65 · market factors 65
ProfitabilityMargins and returns on capital today
10
49
Quality GrowthAre margins and returns improving?
43
65
CashflowEarnings quality: real cash, not paper profit
11
47
Fin. StrengthBalance sheet, leverage, solvency risk
59
72
InvestmentDisciplined investing over empire-building
92
76
Low VolatilityCalm price path (market factor)
48
83
MomentumPrice trend over the last 3–12 months (market factor)
12
56
52W MomentumDistance to the 52-week high (market factor)
0
60
Net IssuanceShare count: buybacks or dilution?
14
100

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyCyclopharmPrice A$0.46McKessonPrice $881
DCF Modelsn/a+10%close to the price$969
Earnings-Basedn/a-50%below the price$444
Dividend Discountn/a-93%below the price$57.26
Multiplesn/a-4%close to the price$848
Asset-Based-70%below the priceA$0.14n/a
Growth DCFn/a+7%close to the price$944
Economic Profitn/a-44%below the price$497
Growth Earningsn/a-20%below the price$708
Minimum-70%below the priceA$0.14-93%below the price$57.26
Maximum-70%below the priceA$0.14+10%close to the price$969
Median-70%below the priceA$0.14-20%below the price$708
Geometric mean-70%below the priceA$0.14-44%below the price$492

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Cyclopharm: 1 of 1 models see the stock below the current price.

McKesson: 13 of 23 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Cyclopharm
Price A$0.46
Fair Value A$0.08
Bear A$0.05Bull A$0.09
McKesson
Price $881
Fair Value $819
Bear $605Bull $1,034

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Cyclopharm · Health Care

Quality score34 · bottom 25%
Fair value upside-83% · bottom 25%

McKesson · Health Care

Quality score66 · Top 25%
Fair value upside-7% · above median

Bottom line

As of Sep 25, 2026, Fair Value Calculator sees McKesson as the less overvalued of the two: Cyclopharm trades at A$0.46 versus a fair value of A$0.08 (-83%), while McKesson trades at $881 versus $819 (-7%).

McKesson has the higher quality score (66/100).

Open McKesson live analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.